



US009511066B2

(12) **United States Patent**
Caruso et al.

(10) **Patent No.:** **US 9,511,066 B2**

(45) **Date of Patent:** ***Dec. 6, 2016**

(54) **ABUSE-RESISTANT
CONTROLLED-RELEASE OPIOID DOSAGE
FORM**

2800/20;A61Q 19/00; A61Q 1/02; A61Q
19/08; A45D 40/262

See application file for complete search history.

(71) Applicant: **Purdue Pharma L.P.**, Stamford, CT
(US)

(56) **References Cited**

U.S. PATENT DOCUMENTS

(72) Inventors: **Frank S. Caruso**, Colts Neck, NJ (US);
Huai-Hung Kao, Syosset, NY (US)

2,770,569	A	11/1956	Fromherz et al.
3,133,132	A	5/1964	Loeb et al.
3,173,876	A	3/1965	Zobrist
3,173,877	A	3/1965	Jackson et al.
3,276,586	A	10/1966	Rosaen
3,332,950	A	7/1967	Blumberg et al.
3,493,657	A	2/1970	Lewenstein et al.
3,541,005	A	11/1970	Strathmann et al.
3,541,006	A	11/1970	Bixler et al.
3,546,876	A	12/1970	Fokker et al.
3,676,557	A	7/1972	Lachman et al.
3,773,955	A	11/1973	Pachter et al.
3,845,770	A	11/1974	Theeuwes et al.
3,879,555	A	4/1975	Pachter et al.
3,916,889	A	11/1975	Russell
3,916,899	A	11/1975	Theeuwes et al.
3,950,508	A	4/1976	Mony et al.
3,965,256	A	6/1976	Leslie
3,966,940	A	6/1976	Pachter
4,063,064	A	12/1977	Saunders et al.
4,088,864	A	5/1978	Theeuwes et al.
4,126,684	A	11/1978	Robson et al.
4,160,020	A	7/1979	Ayer et al.
4,176,186	A	11/1979	Goldberg
4,200,098	A	4/1980	Ayer et al.

(Continued)

(73) Assignee: **Purdue Pharma L.P.**, Stamford, CT
(US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

This patent is subject to a terminal dis-
claimer.

(21) Appl. No.: **15/159,465**

(22) Filed: **May 19, 2016**

(65) **Prior Publication Data**

US 2016/0256456 A1 Sep. 8, 2016

Related U.S. Application Data

(60) Continuation of application No. 15/014,995, filed on
Feb. 3, 2016, now Pat. No. 9,358,230, which is a
continuation of application No. 14/859,195, filed on
Sep. 18, 2015, now Pat. No. 9,283,216, which is a
continuation of application No. 14/725,369, filed on
May 29, 2015, now Pat. No. 9,161,937, which is a
continuation of application No. 14/067,821, filed on
Oct. 30, 2013, now Pat. No. 9,084,729, which is a
continuation of application No. 13/777,537, filed on
Feb. 26, 2013, now abandoned, which is a
continuation of application No. 13/494,431, filed on
Jun. 12, 2012, now abandoned, which is a
continuation of application No. 11/901,232, filed on
Sep. 14, 2007, now abandoned, which is a division of
application No. 10/143,111, filed on May 10, 2002,
now abandoned.

(60) Provisional application No. 60/290,439, filed on May
11, 2001.

(51) **Int. Cl.**
A61K 31/485 (2006.01)
A61K 9/20 (2006.01)
A61K 9/00 (2006.01)
A61K 9/48 (2006.01)

(52) **U.S. Cl.**
CPC **A61K 31/485** (2013.01); **A61K 9/48**
(2013.01)

(58) **Field of Classification Search**
CPC .. A61K 9/2018; A61K 9/2027; A61K 9/2054;
A61K 9/20; A61K 9/0002; A61K 31/485;
A61K 2300/00; A61K 9/48; A61K 8/25;
A61K 8/26; A61K 8/042; A61K 8/0216;
A61K 8/062; A61K 2800/10; A61K

FOREIGN PATENT DOCUMENTS

AU	2002305559	11/2002
CA	2382648	3/2001

(Continued)

OTHER PUBLICATIONS

Abdulla et al., "Axotomy reduces the effect of analgesic opioids yet
increases the effect of nociceptin on dorsal root ganglion neurons";
J of Neuro Sci (1998) vol. 18, pp. 9685-9694.

Abernethy et al., "Randomised, double blind, placebo controlled
crossover trial of sustained release morphine for the management of
refractory dyspnoea," BMJ, vol. 327, pp. 1-6 (2003).

Alvarez-Fuentes et al. "Effectiveness of Repeated Administration of
a New Oral Naltrexone Controlled-Release System in Morphine
Analgesia"; J. Pharm Pharmacol (2001), 53:1201-1205.

(Continued)

Primary Examiner — Blessing M Fubara

(74) *Attorney, Agent, or Firm* — Dechert LLP

(57) **ABSTRACT**

Abuse-resistant, controlled release opioid tablets are a com-
bination containing an opioid antagonist such as naloxone at
a level above that needed to suppress the euphoric effect of
the opioid, if the combination were crushed to break the
controlled release properties causing the opioid and opioid
antagonist to be released as a immediate release product as
a single dose. The controlled release nature of the table
prevents the accumulation of orally effective amounts of
opioid antagonist when taken normally. The opioid antago-
nist is contained in a controlled-release matrix and released,
over time, with the opioid.

30 Claims, No Drawings